恩華藥業(002262.SZ):捐贈202萬元藥品專項用於徐州地區新冠肺炎患者治療
格隆匯2月6日丨恩華藥業(002262.SZ)公佈,目前,新型冠狀病毒感染引發的肺炎疫情仍在不斷蔓延。公司高度關注疫情發展,積極響應黨和政府的號召,積極投身疫情防控工作,在確保全國醫療機構用藥和員工防護的同時,切實履行上市公司社會責任。為此,公司於2020年2月6日通過“徐州市紅十字會”向徐州市承擔新型冠狀病毒感染的肺炎患者收治工作任務的定點醫院捐贈價值202萬元的藥品,包括力月西(咪達唑侖注射液,用於氣管插管和機械通氣患者的鎮靜)、佳蘇侖(鹽酸多沙普侖注射液,用於呼吸衰竭患者)及公司獨家代理產品瑞咯啶(複方電解質注射液,用於治療伴隨或預期出現酸中毒等滲性脱水,補充細胞外液的丟失)等藥品,專項用於徐州地區新型冠狀病毒感染引發肺炎患者的治療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.